H.C. Wainwright raised the firm’s price target on Aquestive Therapeutics to $10 from $9 and keeps a Buy rating on the shares. The company’s virtual investor day provided key insights into its technology platform, product development and long-term strategy, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics Showcases Innovations and Market Strategy
- Aquestive Therapeutics spotlights epinephrine delivery pipeline at Investor Day
- Aquestive Therapeutics Outlines Growth and Product Progress
- Aquestive Therapeutics reiterates expected timing for NDA filing of Anaphylm
- Aquestive Therapeutics price target raised to $15 from $13 at Oppenheimer
Questions or Comments about the article? Write to editor@tipranks.com